Atreca $125 million stock offering
Davis Polk advised the representatives of the several underwriters in connection with a $125 million SEC-registered common stock offering by Atreca, Inc. The common stock is listed on…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Abbott Laboratories $1.3 billion notes offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650…
CryoLife $100 million convertible senior notes offering
Davis Polk advised the initial purchaser in connection with a Rule 144A offering by CryoLife, Inc. of $100 million aggregate principal amount of its 4.250% convertible senior notes due 2025…
ChemoCentryx $346.8 million follow-on offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 5,980,000 shares of common stock of ChemoCentryx, Inc. (which…
Alector $150 million at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Alector, Inc. of shares of its common stock for up to a maximum offering price of …
NeoGenomics $300 million offerings of stock and convertible senior notes
Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by NeoGenomics, Inc. of 4,400,000 shares of its common stock and $175 million…
Coherus BioSciences $200 million convertible notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Coherus BioSciences, Inc. of $200 million aggregate principal amount of its…
Natera $287.5 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Natera, Inc. of $287.5 million aggregate principal amount of its 2.25%…
Nevro $346 million concurrent offerings of stock and convertible senior notes
Davis Polk advised the sole book-running manager in connection with the SEC-registered offering by Nevro Corp. of $189.75 million aggregate principal amount of its 2.75% convertible…
Kala Pharmaceuticals $126.2 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 16,000,000 shares of common stock…